Bone Abstracts

Non-pharmacologic approaches to preserve or increase BMD include whole body vibration (WBV). A meta-analysis and one-year randomized trial concluded that WBV has no effect on BMD in older women; however, previous trials were relatively brief and did not include a sham control group. Therefore, we conducted the Vibration to Improve Bone in Elderly Subjects (‘VIBES’) trial, a randomized, sham-controlled trial of 10 min of daily WBV (0.3 g at 30 Hz) in seniors recruited...

Background: There are no models for estimating risk of fracture in patients taking treatments for osteoporosis. Knowing a patient’s risk of fracture during treatment may help make future treatment decisions; therefore, the development of on-treatment fracture risk models is needed.Methods: To assess on-treatment fracture risk, the analysis included subjects who received denosumab (DMAb) 60 mg Q6 every 6 months for at least 1 year in either FREEDOM o...

Introduction: Administration of antibodies that neutralize sclerostin has been demonstrated to increase bone mass. We report the key findings of a Phase 2 study of the human sclerostin antibody, blosozumab (bmab).Methods: Study GSDB was a randomized, parallel-design, double-blind placebo-controlled study, designed to assess the dose–response relationship of bmab in postmenopausal women with low bone mineral density (BMD; lumbar spine (LS) T...

Romosozumab is an investigational bone-forming agent that inhibits sclerostin. Recent data demonstrated that it stimulated bone formation, decreased bone resorption, and led to rapid and substantial increases in areal bone mineral density (BMD; McClung, J Bone Miner Res 27 (S1) S8–S9, 2012). In a Phase 1b, randomized, double-blind, placebo-controlled, multiple dose study, we studied the effects of romosozumab administered for 3 months and follow-...

A randomized, placebo-controlled phase 2 study evaluated the safety and efficacy of BA058, an analog of hPTHrP(1–34), in postmenopausal women with severe osteoporosis. 221 patients were randomized to received BA058 20, 40, and 80 μg, placebo or teriparatide (TP) 20 μg, by daily s.c. injection. 184 (83%) patients completed an initial 24 weeks of treatment. The mean percent change in lumbar spine BMD at 24 weeks was 1.6% with placebo, 6.7% with BA058 80 μg, a...

Hypogonadism is common in cardiac transplant (CTX) patients and exerts negative effects on bone but also on libido and quality of life.We investigated whether testosterone replacement therapy (TRT) has any positive effects on bone mass, fracture incidence, and quality of sex life when administered in addition to ibandronate (IBN) in hypogonadal CTX recipients. 52 male patients entered the study and received IBN (quarterly 2 μg i.v.). 60% of the pati...